Vorinostat

Target: This ligand targets histone deacetylase enzymes, especially class I and class II HDACs in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for histone deacetylase enzymes, especially class I and class II HDACs. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings histone deacetylase enzymes into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• Histone Degrader PROTAC Design: Vorinostat-derived ligands can be incorporated into PROTAC architectures to recruit E3 ligases and induce ubiquitination of target proteins. This enables systematic evaluation of degradation efficiency, selectivity, and kinetics for epigenetic regulators, supporting mechanistic studies on how HDAC-associated complexes are dismantled at the protein level rather than inhibited.

• HDAC Complex Stability Studies: Using Vorinostat-based binding elements in PROTACs allows researchers to probe the stability of HDAC-containing assemblies. Targeted degradation can reveal compensatory remodeling, downstream acetylation changes, and altered transcriptional programs, providing a clearer causal link between specific HDAC protein removal and functional phenotypes.

• Epigenetic Pathway Mechanism Mapping: Vorinostat PROTACs can be used to dissect epigenetic signaling by selectively degrading HDAC family members. Comparing degradation-driven effects with catalytic inhibition helps distinguish whether observed transcriptional outcomes arise from loss of protein scaffolding, altered chromatin recruitment, or changes in acetylation homeostasis.

• Structure–Activity Degradation Optimization: Vorinostat can serve as a starting ligand for systematic PROTAC optimization, including linker length, attachment position, and E3 ligase selection. This supports structure–activity relationship studies to maximize ternary complex formation, improve degradation potency, and minimize off-target degradation in cellular assays.

Vorinostat is a HDAC target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Vorinostat is characterized by amide/urea/sulfonamide hydrogen-bonding motifs; phenol or alcohol functionality. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The hydroxy or phenolic motif can be considered for ether, carbonate, carbamate, or ester linker attachment after SAR verification. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.